2025 04 21 Owen Yang
Anti-virals for Hepatitis C virus (HCV) infections (#J05AP)
was initially prescribed under the National Health Insurance since 2003 as an
Interferon (#L03AB)
-based therapy, which can be with or without ribavirin as the main antiviral, and this was only used in patients with evidence of liver fibrosis. In 2017 this was replaced with other high efficacy oral Direct Acting Antivirals for HCV, and is available for anyone who has a detectable level of HCV.
More infomation can be found
here.
| J05AP | not available OTC | |
| J05AP01 | not available OTC | |
| J05AP06 | not available OTC | |
| J05AP07 | daclatasvir | not available OTC |
| J05AP08 | sofosbuvir | not available OTC |
| J05AP09 | not available OTC | |
| J05AP51 | sofosbuvir and ledipasvir | not available OTC |
| J05AP53 | not available OTC | |
| J05AP54 | not available OTC | |
| J05AP55 | sofosbuvir and velpatasvir | not available OTC |
| J05AP56 | sofosbuvir, velpatasvir and voxilaprevir | not available OTC |
| J05AP57 | glecaprevir and pibrentasvir | not available OTC |
| J05APX1 | not available OTC | |
| J05APX4 | not available OTC | |
| J05APX5 | not available OTC | |
| J05APX8 | not available OTC |
J05AP Anti-virals for Hepatitis C virus (HCV) infections (Oral, Inhaler)
E.g. Ribavirin.
Prescribing rates
Prescribing rates
